Browsing Tag
HARMONi-6
2 posts
Has Akeso Inc. just exposed the next weak spot in standard lung cancer treatment?
Find out how Akeso Inc.’s ivonescimab survival data could reshape lung cancer treatment and challenge PD-1 drug combinations.
Ivonescimab plus chemotherapy cuts disease progression risk by 40% in first-line squamous NSCLC, outperforming PD-1 rival in Akeso’s HARMONi-6 trial
Find out how Akeso’s ivonescimab plus chemotherapy achieved a 40 % risk reduction over a PD-1 inhibitor combo in squamous NSCLC—and why it’s shaking up the global oncology market!